ATryn development program in Europe #msg-8316050LEO partnership announcement #msg-8345869Notes from the 3Q05 conference call #msg-7767118 EMEA opinion delayed until 2/06 #msg-7957310 Additional color on the delay #msg-6231451 EMEA to conduct inspections (stock was then at 85 cents) #msg-6762063Market opportunity
ATryn vs plasma-derived antithrombin #msg-4372780 Risks of plasma-derived proteins #msg-7306242Which one will doctors prescribe? #msg-7221666Price, availability of commercial plasma-derived AT products #msg-7327529 Heparin contamination?
Miscellaneous info on ATryn and antithrombin #msg-6795394 Potential label expansion (ATryn vs oral anticoagulants) #msg-7268415 ATryn in sepsis (please follow reply chain) #msg-4316445 Bioterror contract with U.S. army #msg-7050226 Abstract on antithrombin deficiency in pregnancy
Articles about GTCB and transgenics #msg-8162424Scientific American (10/05) #msg-6806806Wall St Transcript interview with Tom Newberry (6/05) #msg-6775592Newsweek special issue on healthcare (6/05) #msg-6276428 Worcester, MA Telegram & Gazette (5/05) #msg-7431316Nature Biotechnology (10/04) #msg-4057315The Economist (9/04) #msg-3990950Chemical Market Reporter (9/04) #msg-3631094Boston Herald on bioterror (7/04)